Due to resource constraints, first‐line treatment for patients with Stage IV PCa at CHBAH is restricted to conventional ADT (orchiectomy, LHRH agonists, and first‐generation androgen receptor antagonists). The gene discussed is AR; the disease is posterior cortical atrophy.